Wolters Kluwer Health is the professional’s first choice for knowledge-based information services and decision-support tools for the pharmaceutical, biotechnology and life science industries.
Wolters Kluwer Health is the professional's first choice for knowledge-based information services and decision-support tools for the pharmaceutical, biotechnology and life science industries. We provide unparalleled intelligence from pre-clinical to post-market surveillance marketed under the industry's leading information brands, Adis, IFI Patent Intelligence and Lippincott Williams & Wilkins.
Adis and Lippincott Williams & Wilkins brands offer a diverse collection of more than 300 society-affiliated and proprietary journals and newsletters that are written, edited and peer reviewed by the world's most respected professionals.
Lippincott Williams & Wilkins is backed by a reputation for medical publishing that spans more than 100 years and offers the gold standard in medical textbooks that are written by some of the most prestigious authors in the world.
Adis is responsible for two premier business intelligence databases, R&D Insight and Clinical Trials Insight, which provide information and interpretation to our clients throughout the pharmaceutical product lifecycle.
Wolters Kluwer Health is a unit of WoltersKluwer nv, a leading multinational publisher and information services company with annual revenues (2004) of €3.2 billion and employing approximately 20,000 people worldwide.
For more information please visit http://www.wkhealth.com/ps.htm
For further information on Wolters Kluwer Health products and services, please contact your local office
Chester, United Kingdom:
Tel: +44 1829 772 738
Fax: +44 1829 770 330
Madrid, Spain:
Tel: +34 91 555 4062
Fax: +34 91 555 7689
Munich, Germany
Tel: +49 89 36007 3512
Fax: +49 89 36007 3514
Milan, Italy
Tel: +39 02 423 4562
Fax: +39 02 422 1200
Paris, France
Tel: +33 1 56 99 9700
Fax: + 33 1 56 99 9710
Yardley, PA, USA
Tel: +1 267 757 3400
Fax: +1 267 757 3490
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.